Nephrology

Anuja Java, MD, discusses the diagnostic tests that could lead to a diagnosis of C3G.

Sanjeev Sethi, MD, and Gerald B. Appel, MD, discuss how the kidney biopsy can guide treatment and prognosis in IgAN.

Sanjeev Sethi, MD, discusses the role of the electro microscopy in IgAN.

A prospective study on patients with DR and CKD found no significant effect on renal function shortly after performing fluorescein angiography.

Logistic regression analysis indicated that higher stages of urine albumin creatine ratio were significantly associated with diabetic retinopathy in patients with T2D and diabetic nephropathy.

Sanjeev Sethi, MD, discusses the role of the diagnostic kidney biopsy in IgAN.

Anuja Java, MD, discusses the differential diagnosis of C3G.

Data from patients with eGFR of 20 mL/min/1.73m2 or less from the ADVOCATE trial provide new insight into the effects of avacopan use in patients with lower baseline eGFRs.

Anuja Java, MD; Carla M. Nester, MD, MSA, FASN; and Gerald B. Appel, MD, discuss the consequences of a missed or late diagnosis of C3G.

Anuja Java, MD, and Gerald B. Appel, MD, discuss the challenges of managing C3G in their patients.

Carla M. Nester, MD, MSA, FASN, discusses the differences of C3G in the pediatric versus adult population.

Carla M. Nester, MD, MSA, FASN, gives an overview of C3G.

Carla M. Nester, MD, MSA, FASN, discusses the challenges of IgAN in pediatric patients.

Anuja Java, MD, discusses the heterogeneity of disease activity and recurrence in IgAN transplant population.

Positive phase 2 data from 2 studies on the investigational monoclonal antibody felzartamab designed to deplete CD38+ plasma cells, demonstrated reduced pathogenic antibody levels in primary membranous nephropathy.

An analysis of eGFR changes based on methotrexate use in the MIRROR trial offers new insight into the effects of pegloticase on renal function.

Gerald B. Appel, MD discusses the prevalence of IgAN in various populations and the heterogeneity of the disease.

A panel of glomerular disease specialists provide an overview of immunoglobulin A nephropathy (IgAN).

Hyporesponse to erythropoiesis-stimulating agents was associated with increased rates of red blood cell transfusions and poorer outcomes in patients with chronic kidney disease, highlighting the need for alternative anemia treatments.

Acute inpatient admission was higher in patients with persistent hyporesponse, compared to patients with acute hyporesponse or without hyporesponse.

A phase 2a trial of provides data detailing the effects of inaxaplin, a small molecule APOL1 inhibitor, on urinary protein-to-creatinine ratio in people with focal segmental glomerulosclerosis and two APOL1 variants.

At ACC.23, our editorial team sat down with a pair of leaders in cardiometabolic health to get their perspective on the growing intersectionality of cardiovascular and chronic kidney disease and how patients have been the beneficiaries of this growing recognition.

Results from the NOSTONE trial suggest the incidence of recurrence did not differ among patients receiving hydrochlorothiazide once daily at a dose of 12.5 mg, 25 mg, or 50 mg or once-daily placebo.

The company announced more feedback from the FDA after receiving a Complete Response Letter last March.

Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis.

The 2022 updated guidelines includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease.

There was no significant differences in creatinine or estimated glomerular filtration rate between the readmission group and the no readmission group.

Results from the REGARDS study suggest traditional CKD risk factors were associated with higher risk of incident CKD and eGFR decline in Black individuals, compared to White individuals.

The topline phase 2b data shows both 75 mg and 150 mg doses of atacicept resulted in a 31% mean reduction in proteinuria.

From a topical gene therapy to a debated heart failure option, a litany of unique agents are anticipated for FDA decision in the new year.